Christine Fox, EVP Head of US Commercial at Teva Pharmaceutical Industries Ltd, filed a Form 144 notice of proposed sale of 28,229 ordinary shares on November 20, 2026, with Citigroup Global Markets Inc. named as the executing broker.
Key Highlights
- Seller: Christine Fox, identified in the filing as an officer with the title EVP Head of US Commercial at Teva Pharmaceutical Industries Ltd.
- Shares proposed for sale: 28,229 ordinary shares, with an aggregate market value of $1,095,297.87 as stated in the filing.
- Source of shares: 63,492 ordinary shares were acquired on November 20, 2023, through a restricted share unit award vesting, with payment described as compensation.
- 10b5-1 plan: According to the filing's remarks, "sales were performed to cover obligations under an established 10b51 plan adopted on August 4 2026."
- Broker: Citigroup Global Markets Inc., 390 Greenwich Street, New York, NY 10013, is named as the executing broker.
- Shares outstanding: The filing reports 1,166,826,784 ordinary shares outstanding, with the remarks noting this figure is "based on ordinary shares."
Fox's Proposed Sale of Teva Ordinary Shares Under Rule 144
Teva Pharmaceutical Industries Ltd, an Israel-based pharmaceutical company with its registered address at 124 Dvora Hanevi'a St., Tel Aviv, Israel, is listed on the NYSE. The Form 144 notice, filed on November 20, 2026, covers ordinary shares proposed for sale by Christine Fox, an officer serving as EVP Head of US Commercial, pursuant to Rule 144 under the Securities Act of 1933.
According to the filing, the 28,229 ordinary shares proposed for sale carry an aggregate market value of $1,095,297.87, as stated in the securities information section of the notice. The shares originate from a restricted share unit award vesting transaction dated November 20, 2023, in which Fox acquired 63,492 ordinary shares from Teva Pharmaceutical Industries Limited, with the nature of payment described as compensation. The filing reports no securities sold by Fox during the past three months.
The filing's remarks section states that the shares outstanding figure is "based on ordinary shares" and that "sales were performed to cover obligations under an established 10b51 plan adopted on August 4 2026," with the date of plan adoption listed as August 4, 2026. The approximate date of sale is noted as November 20, 2026, and the securities are listed on the NYSE (SEC File Number 001-16174). The filing was submitted as a live filing with filer CIK 0001998173.
What Was Disclosed
Christine Fox, EVP Head of US Commercial at Teva Pharmaceutical Industries Ltd (NYSE:TEVA), filed a Form 144 notice proposing the sale of 28,229 ordinary shares with an aggregate market value of $1,095,297.87, acquired via a restricted share unit award vesting on November 20, 2023, under a 10b5-1 plan adopted August 4, 2026.




Please wait processing your request...